[go: up one dir, main page]

Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes

Eur J Obstet Gynecol Reprod Biol. 2009 May;144(1):44-7. doi: 10.1016/j.ejogrb.2009.02.006. Epub 2009 Mar 17.

Abstract

Objective: To evaluate if pre-operative GnRH-a modify uterine leiomyoma pseudocapsule and the possible clinical effects of these changes.

Study design: The study was performed at the University Federico II of Naples on 33 premenopausal patients submitted to laparotomic myomectomy after treatment with triptorelin depot. 29 untreated patients formed the control group. The operating time, the intraoperative bleeding and the prompt identification of the cleavage plan between myoma and myometrium were evaluated. The pseudocapsule features and the immunoexpression of PCNA and CD34 in this area were studied.

Results: Treated patients showed lower blood loss and not clearly identifiable cleavage plan, but without any significant increase in the operating time. Treated lesions showed less evident border between myoma and myometrium and lower PCNA and CD34 pseudocapsule immunoexpression than untreated ones.

Conclusion: We propose the changes of leiomyoma pseudocapsule as partial explanations of the reported clinical and surgical findings after pre-operative GnRH-a.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Antigens, CD34 / metabolism
  • Antineoplastic Agents, Hormonal / pharmacology
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Blood Loss, Surgical / prevention & control
  • Cell Proliferation / drug effects
  • Delayed-Action Preparations
  • Female
  • Gonadotropin-Releasing Hormone / agonists*
  • Humans
  • Leiomyoma / blood supply
  • Leiomyoma / drug therapy*
  • Leiomyoma / surgery*
  • Myometrium / metabolism
  • Myometrium / pathology
  • Myometrium / surgery
  • Neovascularization, Pathologic / drug therapy
  • Preoperative Care / methods*
  • Proliferating Cell Nuclear Antigen / metabolism
  • Triptorelin Pamoate / pharmacology
  • Triptorelin Pamoate / therapeutic use*
  • Uterine Neoplasms / blood supply
  • Uterine Neoplasms / drug therapy*
  • Uterine Neoplasms / surgery*

Substances

  • Antigens, CD34
  • Antineoplastic Agents, Hormonal
  • Delayed-Action Preparations
  • Proliferating Cell Nuclear Antigen
  • Triptorelin Pamoate
  • Gonadotropin-Releasing Hormone